IambicTherapeutics Inc., a clinical-stage anti-cancer drug research and technology company, completed its initial public offering in the US, raised US$150 million, and the issue price was set at the midpoint of the promotion range. According to Wednesday's announcement, the company, which has Nvidia's participation, will issue approximately 9.38 million shares at a price of 16 US dollars per share. According to previous filing documents, Iambic's original issue price range was 15 to 17 US dollars per share. According to the issuance price of this IPO, combined with the issued shares disclosed in the filing documents, the San Diego-based company has a market value of 758 million US dollars. According to the application documents, Iambic uses artificial intelligence and machine learning technology to develop new treatments. The company will use the capital raised in this IPO to promote three early-stage anti-cancer drug candidates.

IambicTherapeutics Inc., a clinical-stage anti-cancer drug research and technology company, completed its initial public offering in the US, raised US$150 million, and the issue price was set at the midpoint of the promotion range. According to Wednesday's announcement, the company, which has Nvidia's participation, will issue approximately 9.38 million shares at a price of 16 US dollars per share. According to previous filing documents, Iambic's original issue price range was 15 to 17 US dollars per share. According to the issuance price of this IPO, combined with the issued shares disclosed in the filing documents, the San Diego-based company has a market value of 758 million US dollars. According to the application documents, Iambic uses artificial intelligence and machine learning technology to develop new treatments. The company will use the capital raised in this IPO to promote three early-stage anti-cancer drug candidates.